Interpace Biosciences, Inc. (IDXG)
OTCMKTS
· Delayed Price · Currency is USD
1.750
-0.035 (-1.96%)
Mar 5, 2026, 3:59 PM EST
Interpace Biosciences Employees
Interpace Biosciences had 111 employees as of December 31, 2024. The number of employees increased by 3 or 2.78% compared to the previous year.
Employees
111
Change (1Y)
3
Growth (1Y)
2.78%
Revenue / Employee
$377,613
Profits / Employee
$30,045
Market Cap
48.45M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Longduoduo Company | 52 |
| Aspira Women's Health | 66 |
| Psychemedics | 101 |
| Hypha Labs | 5 |
| Centogene | 384 |
| ProPhase Labs | 96 |
Interpace Biosciences News
- 3 months ago - Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners - GlobeNewsWire
- 4 months ago - Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results - GlobeNewsWire
- 6 months ago - Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting - GlobeNewsWire
- 11 months ago - Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results - GlobeNewsWire
- 1 year ago - PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan - GlobeNewsWire
- 1 year ago - Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk - GlobeNewsWire
- 1 year ago - Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results - GlobeNewsWire